Phase 2
Completed N=43
Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection
Source: ClinicalTrials.gov NCT02175680 ↗Enrolled (actual)
43
Serious AEs
2.3%
Results posted
Apr 2023
Primary outcomePrimary: Time to Virologic Failure After Initiating PRO 140 Monotherapy. — 70.71 days — p=<0.0001
Summary
This study is a Phase 2b study designed to evaluate the efficacy, safety, and tolerability of PRO 140 monotherapy for the maintenance of viral suppression in subjects who are stable on combination antiretroviral therapy.
Consenting subjects will be shifted from their combination antiretroviral regimen to PRO 140 monotherapy for 12 weeks. Total treatment duration with PRO 140 will be 14 weeks with the one week overlap of existing retroviral regimen and PRO 140 at the beginning of the study treatment, and one week overlap at the end of the treatment in subjects who do not experience virologic failure.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Time to Virologic Failure After Initiating PRO 140 Monotherapy. |
70.71 | <0.0001 sig |
| SECONDARY Proportion of Subjects With Virologic Failure |
0.439 | — |
| SECONDARY Mean Change From Baseline in Viral Load |
0.10; 0.01; -0.13; -0.25; -0.76; -0.88 | — |
| SECONDARY Change in Viral Load at the Last Virologic Failure Visit. |
-1.78 | — |
| SECONDARY Mean Change in CD4 Cell Count by Visit |
32.05; -33.14; -12.78; 33.42; -3.26; 47.50 | — |
| SECONDARY Mean Change in CD4 Cell Count |
18.97 | — |
| SECONDARY Q1 QOL Health Status |
0; 1; 6; 10; 13; 11 | — |
| SECONDARY Q2 QOL Current State of Health |
82.3; 83.8; 80.9; 84.9; 78.0 | — |
Eligibility Criteria
Inclusion Criteria
- Males and females, age ≥18 years
- Exclusive CCR5-tropic virus at Screening Visit as determined by Trofile™ DNA Assay
- On stable antiretroviral therapy for last 12 months
- Subject has two or more potential alternative antiretroviral regimen options to consider.
- No documented detectable viral loads (HIV-1 RNA 200 cells/mm3
Exclusion Criteria
- CXCR4-tropic virus or dual/mixed tropic (R5X4) virus determined by the Trofile™ DNA Assay at the Screening Visit
- Hepatitis B infection as manifest by the presence of Hepatitis B surface antigen (HBsAg)
- Any acquired immune deficiency syndrome (AIDS)-defining illness according to the 1993 Centers for Disease Control and Prevention (CDC) AIDS surveillance definition
- Prior use of any entry, attachment, CCR5 co-receptor, or fusion inhibitor, including PRO 140.
- Any other clinical condition that, in the Investigator's judgment, would potentially compromise study compliance or the ability to evaluate safety/efficacy
Data sourced from ClinicalTrials.gov (NCT02175680). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.